ORTHOReBIRTH USA Launches ReBOSSIS Quick Delivery System
ReBOSSIS QDS is now being introduced to the biologic market
GEORGETOWN, Texas, Nov. 28, 2018 /PRNewswire-PRWeb/ -- ORTHOReBIRTH USA is bringing a new product to the medical device industry﹘the ReBOSSIS Quick Delivery System (QDS). ReBOSSIS QDS is a syringe designed to access hard-to-reach areas in orthopedic and spine surgical procedures. These transparent tubes enhance product visualization and precise product placement, and the pre-filled syringes allow for ease of hydration and controlled delivery of ReBOSSIS.
"With the Quick Delivery System, surgeons can now achieve precise product placement," says Doris Blake, president and COO of ORTHOReBIRTH USA. "We have already seen numerous successful procedures utilize ReBOSSIS, and this new system will lead to many more."
ORTHOReBIRTH USA markets ReBOSSIS, the only biosynthetic scaffold with electrospun microfiber construction, to surgeons practicing around the world. ReBOSSIS is proven to support cell activation, retention and proliferation. It offers superior handling characteristics and up to 54% compression & recovery, while maintaining integrity during & after placement.
Visit the company's website or email ORTHOReBIRTH USA to learn more.
About ORTHOReBIRTH USA
We recognize the challenges associated with orthopedic surgery—for patients, surgeons and hospitals alike. We are committed to marketing cutting-edge orthopedic biologics that improve patients' quality of life and offer superior outcomes. We have carried out extensive studies on what makes biologic materials successful and have used that knowledge to engineer world-class products for use in a host of orthopedic surgical procedures. ORTHOReBIRTH USA is proud to market premium orthopedic biologics to surgeons practicing around the world. Recently, ORTHOReBIRTH USA also signed a letter of intent with Dr. Loubert S. Suddaby to develop new biologics.
SOURCE ORTHOReBIRTH USA
Share this article